Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gains from Sales and Divestitures: 2022-2025

Historic Gains from Sales and Divestitures for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to $698,136.

  • Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures rose 15.63% to $698,136 in Q3 2025 from the same period last year, while for Sep 2025 it was $698,136, marking a year-over-year increase of 15.63%. This contributed to the annual value of $680,031 for FY2024, which is 30.41% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Gains from Sales and Divestitures of $698,136 as of Q3 2025, which was up 104.01% from $342,204 recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Gains from Sales and Divestitures high stood at $698,136 for Q3 2025, and its period low was $54,349 during Q1 2025.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Gains from Sales and Divestitures value was $342,204 (recorded in 2025), while the average stood at $373,169.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first spiked by 107.91% in 2023, then crashed by 52.54% in 2024.
  • Quarterly analysis of 4 years shows Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures stood at $250,805 in 2022, then spiked by 107.91% to $521,440 in 2023, then skyrocketed by 30.41% to $680,031 in 2024, then climbed by 15.63% to $698,136 in 2025.
  • Its Gains from Sales and Divestitures was $698,136 in Q3 2025, compared to $342,204 in Q2 2025 and $54,349 in Q1 2025.